BSc Pharm, Biochem PhD
saida.ortolano@iisgaliciasur.es
Phone: +34 986217466 or +34 645219165
ORCID ID: 0000-0002-1098-3376
Postal Address:
Rare Diseases and Pediatric Medicine Group
Health Research Institute Galicia Sur
Hospital Álvaro Cunqueiro, bloque técnico planta 2B
Clara Campoamor 341 36213 Vigo (Spain)
We are involved in clinical diagnosis through screening studies, variants characterization and histopathological analysis. We look at molecular mechanisms of these disorders to unravel the link between LSDs, neurodegenerative diseases, chronic inflammation or cellular senescence, through the study of lysosomal function.
Finally we are seeking to develop more efficient therapies by developing new gene therapy vectors and small molecules.
• Tania Pérez Marquez, Lab Technician
• Marta Alves Villar, Lab Technician
• Adrián Alonso Núñez, PhD Student
Collaborating Physicians
• Julián Fernandez Martín, Internal Medicine
Rare Diseases & Pediatric Medicine Group
• Alberto Rivera, Internal Medicine
Systemic Autoimmune Diseases & Thrombosis
• Beatriz San Millán Tejado, Pathological Anatomy
Rare Diseases & Pediatric Medicine Group
• Ana Concheiro Guisán, Cristina Melcón Crespo, Pediatrics
Rare Diseases & Pediatric Medicine Group
• Pedro Besada Pereira and Carmen Terán , BIOILS Group. Organic Chemistry Dep., Universidade de Vigo
• Maria Grazia Biferi, Sorbonne Université, INSERM, Institute of Myology, Centre of Research in Myology, 75013 Paris, France
• Giuseppe Ronzitti, Genethon, France
• Rosario Sánchez Martínez, Hospital General de Alicante
• Remedios Garofano López, Hospital de Torrecardenas, Almería
• Manuel López Mendoza, Hospital Virgen del Rocío de Sevilla
• Mari Luz Couce Pico, Hospital Clínico de Santiago de Compostela
1) Validación de biomarcadores pronósticos para la Enfermedad de Fabry. Program: Acción Estrategica en IIS-Salud Carlos III (Proyectos de Investigación). PI22/00827. Time period: 01/01/2023-31/12/2025
Total ammount: 99.220,00€
2) Sponsored Research Agreement: “Preclinical development of new treatments for LDs”. Program: International Pharmaceutical Company (CONFIDENTIAL). OT-SO-01. Time period: 01/08/2019-31/12/2022
Total ammount: 704.450,86€
3) Study of the immunitary system dysfunction in Fabry disease. Program: Acción Estrategica en IIS-Salud Carlos III (Proyectos de Investigación) PI19-01886 Time period: 01/01/2020-31/12/2022 Total ammount: 75.020 €
4) Inflammatory Patterns in Fabry Disease: Effect of Enzyme Replacement Therapy on the Innate and Adaptive Immune Response Program: Investigator Initiated Research: Shire Pharmaceuticals-Takeda Time period: 30/10/2018 – 30/04/2020 Total Amount: 62.101,15€
5) Functional evaluation of an AAV9 based vector expressing alpha-Galactosidase A for potential gene therapy of Fabry disease. Program: VAINCRE LES MALADIES LYSOSOMALES, Paris, Francia. Time period: 01/01/2018 – 31/12/2018 Total Amount: 25.000 €
6) Fabry Disease: Molecular Mechanisms and biological tools for its treatment. Program: Acción Estratégica en Salud, Instituto de Salud Carlos III (Proyectos de Investigación) Code: PI-11-00842Time Period: 01/01/2012 – 31/12/2014 Total Amount: 90.514,88 €
Diagnostic methods implementation in Fabry Disease. Cristina Melcón Crespo Universidad de Santiago de Compostela 17/07/2019. Sobresaliente Cum Laude.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.